HLX17 completes first patient dosing

Fuhong Hanlin announcement: The international multicenter Phase 1 clinical study of HLX17, a biosimilar of pembrolizumab independently developed by the company, in patients with various resected solid tumors has completed the first dosing of a patient in China. This study is a multicenter, randomized, double-blind, parallel-controlled Phase 1 clinical study aimed at evaluating the pharmacokinetic characteristics, efficacy, safety, and immunogenicity similarity of HLX17 and KEYTRUDA in subjects with various resected solid tumors.